Genedrive shares jump as hails UKCA mark for test; aims for EU CE mark
6th Sep 2023 11:18
(Alliance News) - Genedrive PLC on Wednesday said that its CYP2C19 point of care test achieved marking registration in the UK, known as UKCA. Read More
(Alliance News) - Genedrive PLC on Wednesday said that its CYP2C19 point of care test achieved marking registration in the UK, known as UKCA. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
Genedrive PLC - Manchester, England-based point-of-care molecular diagnostics company - Awarded a multi-partner grant for the validation of its CYP2X19 ID kit from Innovate UK and the UK government Innovation Accelerator programme. Says the 'Devote' grant will allow it to offer critical clinical tests in NHS settings. Read More
(Alliance News) - Genedrive PLC on Friday said draft guidance from the UK's National Institute for Health & Care Excellence has recommended that CYP2C19 genotyping should be used to manage ischemic stroke patients. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
Genedrive PLC - Manchester, England-based point-of-care molecular diagnostics company - Reports revenue in the six months to December 31 of GBP20,000 compared to nothing a year prior, and an operating loss of GBP2.7 million from GBP2.8 million. Confident that the company will see an acceleration of revenues through 2023 and going forwards. Agrees GBP5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd with an initial drawn amount of GBP2 million, expected to be received in early April. Proceeds will be used towards the commercialisation of the antibiotic induced hearing loss test, Genedrive MT-RNR1 ID Kit and enhancing the Genedrive platform as well as providing additional working capital. Directors believe the facility is the best option available at present. Read More
(Alliance News) - Genedrive PLC on Thursday said the UK National Institute for Health & Care Excellence ratified and finalised its recommendation that Genedrive's hearing loss gene screening test MT-RNR1 ID kit can be used by the NHS. Read More
(Alliance News) - Stocks in London are set to build on Wednesday's gains, as risk appetite recovers following the recent banking turmoil. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - Genedrive PLC on Monday reported further progress in the rollout of its hearing loss gene screening test in the UK. Read More
(Alliance News) - Stock prices in London opened lower on Monday morning as the emergency takeover of beleaguered lender Credit Suisse over the weekend failed to quell market turmoil. Read More
(Alliance News) - Stock prices in London were largely higher at midday on Thursday, thanks to a strong set of results from drug maker AstraZeneca and renewed takeover talks for lender Standard Chartered. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
(Alliance News) - Genedrive PLC on Thursday said the UK National Institute for Health & Care Excellence has preliminarily recommended its antibiotic hearing loss test, the MT-RNR1 ID kit. Read More
(Alliance News) - Stock prices in London opened higher on Thursday, as investors digested a mixed set of UK company earnings. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
Genedrive PLC - Manchester-based molecular diagnostics company - Reports that 21% of its shareholders voted against resolution 3 for the reappointment Tom Lindsay as a director at its annual general meeting on Thursday. 32% of its shareholders voted against resolution 5 for the reappointment of David Budd as a director, and 25% of shareholders voted against resolution 6 for the reappointment of Ian Gilham as a director. Adds that 25% of shareholders voted against resolution 10, to authorise the directors to allot equity securities in the capital. Read More